A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 20 Aug 2017
At a glance
- Drugs Ramucirumab (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms RELAY
- Sponsors Eli Lilly
- 13 Jun 2017 Planned End Date changed from 1 Apr 2020 to 1 Dec 2019.
- 13 Jun 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Oct 2018.
- 22 Aug 2015 Planned number of patients changed from 462 to 550, as reported by European Clinical Trials Database.